The Eisai:University College London (UCL) Collaboration
A major collaboration to discover and develop novel therapeutic agents for the treatment of neurological diseases such as Alzheimer’s, Parkinson’s and other related neurodegenerative disorders.
The alliance brings together the strengths of both organizations: UCL providing its world-class early-stage translational research and Eisai providing its drug discovery and development expertise.
To date this model has delivered four exciting new research projects that are focussed on key areas of interest for disease intervention including: mitochondrial dysfunction, neuroinflammation and protein misfolding and aggregation. These projects have already benefited from the generation of tool reagents, compounds and antibodies; access to Eisai’s compound library in Hatfield, resulting in the completion of two high throughput screens; significant input from the wider Eisai organisation including medicinal chemistry, screening technologies and drug metabolism and pharmacokinetic profiling.
As these existing projects mature we are actively exploring ideas for new proposals in key research areas of interest for neurodegenerative disease intervention including: mitochondrial dysfunction, protein aggregation and misfolding, neuroinflammation, endoplasmic reticulum stress, synaptic plasticity and neurovascular disease.
For further information about Eisai:UCL collaboration click here.